دورية أكاديمية
Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin.
| العنوان: | Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. |
|---|---|
| المؤلفون: | Cho WC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Saade R; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Nagarajan P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Aung PP; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Marques-Piubelli ML; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hudgens C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ledesma D; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Nelson K; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ivan D; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zhang M; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Torres-Cabala CA; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Campbell M; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Alhalabi O; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Prieto VG; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Esmaeli B; Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Curry JL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
| المصدر: | Journal of cutaneous pathology [J Cutan Pathol] 2024 May; Vol. 51 (5), pp. 360-367. Date of Electronic Publication: 2024 Jan 10. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 0425124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0560 (Electronic) Linking ISSN: 03036987 NLM ISO Abbreviation: J Cutan Pathol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Malden, MA : Wiley Original Publication: Copenhagen, Blackwell Munksgaard. |
| مواضيع طبية MeSH: | Adenocarcinoma, Papillary* , Antibodies, Monoclonal* , Nectins* , Neoplasms, Adnexal and Skin Appendage*/drug therapy , Skin Neoplasms*/pathology, Humans ; Adenoma ; Carcinoma, Ductal ; Carcinoma, Skin Appendage ; Carcinoma, Transitional Cell ; Sebaceous Gland Neoplasms/pathology ; Sweat Gland Neoplasms/drug therapy |
| مستخلص: | Background: Enfortumab vedotin (EV) is an antibody-drug conjugate directed against Nectin-4 that is used to treat urothelial carcinoma. Nectin-4 is inherently expressed in the skin and adnexal structures. Since therapeutic options for cutaneous adnexal carcinomas are limited, we sought to evaluate Nectin-4 expression in adnexal carcinomas and benign adnexal neoplasms to identify tumors that are potentially targetable with EV. Methods: Eight sebaceous carcinomas (seven periocular and one lymph node metastasis), eight digital papillary adenocarcinomas, seven squamoid eccrine ductal carcinomas, eight poromas, eight trichilemmomas, and seven sebaceous adenomas were subjected to immunohistochemical staining for anti-Nectin-4 antibody. H-scores for Nectin-4 expression were calculated. Results: Benign adnexal neoplasms had a significantly lower mean (±SD) Nectin-4 H-score (142.6 ± 39.1) than did the adnexal carcinomas (198 ± 90.8; p = 0.006). Nectin-4 was expressed in 91% (21/23) of adnexal carcinomas. Sebaceous carcinomas frequently exhibited high expression of Nectin-4 (88% [7/8]), with a mean (±SD) H-score (258.1 ± 58.4) significantly higher than those for digital papillary adenocarcinomas (197.5 ± 52.5; p = 0.035) and squamoid eccrine ductal carcinomas (131.4 ± 114.1; p = 0.031). Sebaceous carcinomas also had significantly higher H-scores than did sebaceous adenomas (186.4 ± 25.0; p = 0.013). Conclusions: Increased Nectin-4 expression in a subset of cutaneous adnexal carcinomas, particularly sebaceous carcinomas, reveals that EV is a potential therapeutic option for these tumors. (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.) |
| References: | Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. Cancer. 2009;115(1):158‐165. doi:10.1002/cncr.23952. Dores GM, Curtis RE, Toro JR, Devesa SS, Fraumeni JF Jr. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir‐Torre syndrome. Cancer. 2008;113(12):3372‐3381. doi:10.1002/cncr.23963. Wu A, Rajak SN, Chiang CJ, Lee WC, Huilgol SC, Selva D. Epidemiology of cutaneous sebaceous carcinoma. Australas J Dermatol. 2021;62:57‐59. doi:10.1111/ajd.13387. Tripathi R, Chen Z, Li L, Bordeaux JS. Incidence and survival of sebaceous carcinoma in the United States. J Am Acad Dermatol. 2016;75(6):1210‐1215. doi:10.1016/j.jaad.2016.07.046. Veld EHI, Keizer R, Post N, et al. Outcome after treatment for sebaceous carcinoma: a multicenter study. J Surg Oncol. 2022;125(4):730‐735. doi:10.1002/jso.26774. Sa HS, Rubin ML, Xu S, et al. Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients. Br J Ophthalmol. 2019;103:980‐984. doi:10.1136/bjophthalmol‐2018‐312635. Owen JL, Kibbi N, Worley B, et al. Sebaceous carcinoma: evidence‐based clinical practice guidelines. Lancet Oncol. 2019;20(12):e699‐e714. doi:10.1016/S1470‐2045(19)30673‐4. Kandl TJ, Sagiv O, Curry JL, et al. High expression of PD‐1 and PD‐L1 in ocular adnexal sebaceous carcinoma. Onco Targets Ther. 2018;7(9):e1475874. doi:10.1080/2162402X.2018.1475874. Tetzlaff MT, Curry JL, Ning J, et al. Distinct biological types of ocular adnexal sebaceous carcinoma: HPV‐driven and virus‐negative tumors arise through nonoverlapping molecular‐genetic alterations. Clin Cancer Res. 2019;25(4):1280‐1290. doi:10.1158/1078‐0432.CCR‐18‐1688. Reymond N, Fabre S, Lecocq E, Adelaïde J, Dubreuil P, Lopez M. Nectin4/PRR4, a new afadin‐associated member of the nectin family that trans‐interacts with nectin1/PRR1 through V domain interaction. J Biol Chem. 2001;276(46):43205‐43215. doi:10.1074/jbc.M103810200. Heath EI, Rosenberg JE. The biology and rationale of targeting nectin‐4 in urothelial carcinoma. Nat Rev Urol. 2021;18(2):93‐103. doi:10.1038/s41585‐020‐00394‐5. Takai Y, Irie K, Shimizu K, Sakisaka T, Ikeda W. Nectins and nectin‐like molecules: roles in cell adhesion, migration, and polarization. Cancer Sci. 2003;94(8):655‐667. doi:10.1111/j.1349‐7006.2003.tb01499.x. Challita‐Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody‐drug conjugate targeting nectin‐4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003‐3013. doi:10.1158/0008‐5472.CAN‐15‐1313. Murata M, Ito T, Tanaka Y, Kaku‐Ito Y, Furue M. NECTIN4 expression in extramammary Paget's disease: implication of a new therapeutic target. Int J Mol Sci. 2020;21(16):5891. doi:10.3390/ijms21165891. Takahashi S, Uemura M, Kimura T, et al. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma. Invest New Drugs. 2020;38(4):1056‐1066. doi:10.1007/s10637‐019‐00844‐x. M‐Rabet M, Cabaud O, Josselin E, et al. Nectin‐4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple‐negative breast cancer. Ann Oncol. 2017;28(4):769‐776. doi:10.1093/annonc/mdw678. Moussa M, Papatsoris A, Abou Chakra M, Dellis A. Profile of enfortumab vedotin in the treatment of urothelial carcinoma: the evidence to date. Drug Des Devel Ther. 2021;15:453‐462. doi:10.2147/DDDT.S240854. U.S. Food and Drug Administration. FDA approves new type of therapy to treat advanced urothelial cancer. Accessed April 4, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-type-therapy-treat-advanced-urothelial-cancer. Hashimoto H, Tanaka Y, Murata M, Ito T. Nectin‐4: a novel therapeutic target for skin cancers. Curr Treat Options Oncol. 2022;23(4):578‐593. doi:10.1007/s11864‐022‐00940‐w. ClinicalTrials.gov. A study to evaluate enfortumab vedotin in subjects with previously treated locally advanced or metastatic malignant solid tumors (EV‐202). Accessed April 4, 2023. https://clinicaltrials.gov/ct2/show/NCT04225117. Tanaka Y, Murata M, Shen CH, Furue M, Ito T. NECTIN4: a novel therapeutic target for melanoma. Int J Mol Sci. 2021;22(2):976. doi:10.3390/ijms22020976. Tanaka Y, Murata M, Oda Y, Furue M, Ito T. NECTIN cell adhesion molecule 4 (NECTIN4) expression in cutaneous squamous cell carcinoma: a new therapeutic target? Biomedicine. 2021;9(4):355. doi:10.3390/biomedicines9040355. Ito T, Hashimoto H, Tanaka Y, et al. NECTIN4 expression in sebaceous and sweat gland carcinoma. Eur J Dermatol. 2022;32(2):181‐186. doi:10.1684/ejd.2022.4241. Nishiwada S, Sho M, Yasuda S, et al. Nectin‐4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res. 2015;34(1):30. doi:10.1186/s13046‐015‐0144‐7. Deng H, Shi H, Chen L, Zhou Y, Jiang J. Over‐expression of Nectin‐4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients. Cancer Cell Int. 2019;19:106. doi:10.1186/s12935‐019‐0824‐z. Mizutani K, Kedashiro S, Maruoka M, Ueda Y, Takai Y. Nectin‐like molecule‐4/cell adhesion molecule 4 inhibits the ligand‐induced dimerization of ErbB3 with ErbB2. Sci Rep. 2017;7(1):11375. doi:10.1038/s41598‐017‐10107‐5. Sakisaka T, Ikeda W, Ogita H, Fujita N, Takai Y. The roles of nectins in cell adhesions: cooperation with other cell adhesion molecules and growth factor receptors. Curr Opin Cell Biol. 2007;19(5):593‐602. doi:10.1016/j.ceb.2007.09.007. Zhang Y, Liu S, Wang L, et al. A novel PI3K/AKT signaling axis mediates Nectin‐4‐induced gallbladder cancer cell proliferation, metastasis and tumor growth. Cancer Lett. 2016;375(1):179‐189. doi:10.1016/j.canlet.2016.02.049. Siddharth S, Goutam K, Das S, et al. Nectin‐4 is a breast cancer stem cell marker that induces WNT/β‐catenin signaling via Pi3k/Akt axis. Int J Biochem Cell Biol. 2017;89:85‐94. doi:10.1016/j.biocel.2017.06.007. Zhang Y, Chen P, Yin W, Ji Y, Shen Q, Ni Q. Nectin‐4 promotes gastric cancer progression via the PI3K/AKT signaling pathway. Hum Pathol. 2018;72:107‐116. doi:10.1016/j.humpath.2017.10.034. Hao RT, Zheng C, Wu CY, et al. NECTIN4 promotes papillary thyroid cancer cell proliferation, migration, and invasion and triggers EMT by activating AKT. Cancer Manag Res. 2019;11:2565‐2578. doi:10.2147/CMAR.S190332. Li P, Hou F, Wang S, Luo N, Qi Y, Wang Y. A novel NECTIN4–NTRK1 fusion identified in a lung squamous cell carcinoma patient with MSI‐H. J Cancer Res Clin Oncol. 2021;147(8):2483‐2486. |
| فهرسة مساهمة: | Keywords: Nectin‐4; digital papillary adenocarcinoma; enfortumab vedotin; sebaceous carcinoma; squamoid eccrine ductal carcinoma |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) DLE8519RWM (enfortumab vedotin) 0 (Nectins) |
| تواريخ الأحداث: | Date Created: 20240111 Date Completed: 20240409 Latest Revision: 20240415 |
| رمز التحديث: | 20240416 |
| DOI: | 10.1111/cup.14579 |
| PMID: | 38200650 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1600-0560 |
|---|---|
| DOI: | 10.1111/cup.14579 |